GERON CORP Available-for-sale Securities
GERON CORP (GERN) had Available-for-sale Securities of $162.05 million as of 2018-06-30, per its 10-Q filed 2018-07-31.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecurities · last filed 2018-07-31
- 2018-06-30: Available-for-sale Securities $162.05M.
- 2018-03-31: Available-for-sale Securities $95.05M.
- 2017-12-31: Available-for-sale Securities $92.59M.
- 2017-09-30: Available-for-sale Securities $102.55M.
| Period end | Available-for-sale Securities |
|---|---|
| 2018-06-30 | $162.05M 10-Q · filed 2018-07-31 |
| 2018-03-31 | $95.05M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $92.59M 10-Q · filed 2018-07-31 |
| 2017-09-30 | $102.55M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $110.31M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $106.56M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $115.99M 10-K · filed 2018-03-16 |
| 2016-09-30 | $123.66M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $127.92M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $128.82M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $125.19M 10-K · filed 2017-03-01 |
| 2015-09-30 | $134.68M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $140.95M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $153.39M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $127.58M 10-K · filed 2016-03-10 |
| 2014-09-30 | $134.60M 10-Q · filed 2014-11-05 |
| 2014-06-30 | $137.31M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $141.33M 10-Q · filed 2014-05-01 |
| 2013-12-31 | $52.23M 10-K · filed 2015-03-11 |
| 2013-09-30 | $56.62M 10-Q · filed 2013-11-07 |
| 2013-06-30 | $61.97M 10-Q · filed 2013-08-08 |
| 2012-12-31 | $73.47M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |